KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non-cash Items (2018 - 2019)

Amneal Pharmaceuticals has reported Non-cash Items over the past 2 years, most recently at $2.1 million for Q4 2019.

  • For Q4 2019, Non-cash Items fell 20.3% year-over-year to $2.1 million; the TTM value through Dec 2019 reached $2.1 million, down 20.3%, while the annual FY2019 figure was $2.1 million, 20.3% down from the prior year.
  • Non-cash Items for Q4 2019 was $2.1 million at Amneal Pharmaceuticals, down from $2.6 million in the prior quarter.
  • Over five years, Non-cash Items peaked at $2.6 million in Q4 2018 and troughed at $2.1 million in Q4 2019.